Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/ref...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-01-01
coleção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952924005585
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!